Older Age and High α-Fetoprotein Predict Higher Risk of Hepatocellular Carcinoma in Chronic Hepatitis-B-Related Cirrhotic Patients Receiving Long-Term Nucleos(t)ide Analogue Therapy
Background: Nucleos(t)ide analogues (NUCs) were proved to reduce hepatocellular carcinoma (HCC) development in chronic hepatitis B (CHB) patients, but data were limited on their efficacy in cirrhotic CHB patients. Methods: A total of 447 cirrhotic CHB patients treated with tenofovir/entecavir were r...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/12/9/2085 |
| _version_ | 1797489489158864896 |
|---|---|
| author | Yuh-Ying Liu Chih-Lang Lin Cheng-Hao Weng Pei-Hung Chang Cheng-Hung Chien Kuang-Chen Huang Man-Chin Hua Ching-Chih Hu |
| author_facet | Yuh-Ying Liu Chih-Lang Lin Cheng-Hao Weng Pei-Hung Chang Cheng-Hung Chien Kuang-Chen Huang Man-Chin Hua Ching-Chih Hu |
| author_sort | Yuh-Ying Liu |
| collection | DOAJ |
| description | Background: Nucleos(t)ide analogues (NUCs) were proved to reduce hepatocellular carcinoma (HCC) development in chronic hepatitis B (CHB) patients, but data were limited on their efficacy in cirrhotic CHB patients. Methods: A total of 447 cirrhotic CHB patients treated with tenofovir/entecavir were retrospectively analyzed and divided into HCC (<i>n</i> = 48) and non-HCC (<i>n</i> = 399) groups. The median follow-up period was 62.1 months. Results: A total of 48 patients (10.7%) developed HCC during surveillance. The annual incidence rate of HCC was 2.04 per 100 person-years. The cumulative incidence of HCC was 0.9%, 9.8%, and 22.1% at 1, 5, and 10 years, respectively. Significant predictors for HCC identified using a multiple Cox regression analysis were age ≥50 years (hazard ratio (HR): 2.34) and α-fetoprotein (AFP) ≥8 ng/mL (HR: 2.05). The incidence rate of HCC was 8.67-fold higher in patients with age ≥50 years and AFP ≥8 ng/mL (3.14 per 100 person-years) than those with age <50 years and AFP <8 ng/mL (0.36 per 100 person-years). Conclusions: Cirrhotic CHB patients with age <50 years and AFP <8 ng/mL had the lowest annual incidence of HCC. However, those with age ≥50 years or/and AFP ≥8 ng/mL had a significantly higher risk for HCC development and warrant a careful surveillance schedule. |
| first_indexed | 2024-03-10T00:18:16Z |
| format | Article |
| id | doaj.art-cb67d7217bd34cb681438b0e865d34a8 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-10T00:18:16Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-cb67d7217bd34cb681438b0e865d34a82023-11-23T15:48:30ZengMDPI AGDiagnostics2075-44182022-08-01129208510.3390/diagnostics12092085Older Age and High α-Fetoprotein Predict Higher Risk of Hepatocellular Carcinoma in Chronic Hepatitis-B-Related Cirrhotic Patients Receiving Long-Term Nucleos(t)ide Analogue TherapyYuh-Ying Liu0Chih-Lang Lin1Cheng-Hao Weng2Pei-Hung Chang3Cheng-Hung Chien4Kuang-Chen Huang5Man-Chin Hua6Ching-Chih Hu7Liver Research Unit, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Keelung 20401, TaiwanLiver Research Unit, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Keelung 20401, TaiwanCollege of Medicine, Chang Gung University, Taoyuan 33302, TaiwanCollege of Medicine, Chang Gung University, Taoyuan 33302, TaiwanLiver Research Unit, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Keelung 20401, TaiwanLiver Research Unit, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Keelung 20401, TaiwanCollege of Medicine, Chang Gung University, Taoyuan 33302, TaiwanLiver Research Unit, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Keelung 20401, TaiwanBackground: Nucleos(t)ide analogues (NUCs) were proved to reduce hepatocellular carcinoma (HCC) development in chronic hepatitis B (CHB) patients, but data were limited on their efficacy in cirrhotic CHB patients. Methods: A total of 447 cirrhotic CHB patients treated with tenofovir/entecavir were retrospectively analyzed and divided into HCC (<i>n</i> = 48) and non-HCC (<i>n</i> = 399) groups. The median follow-up period was 62.1 months. Results: A total of 48 patients (10.7%) developed HCC during surveillance. The annual incidence rate of HCC was 2.04 per 100 person-years. The cumulative incidence of HCC was 0.9%, 9.8%, and 22.1% at 1, 5, and 10 years, respectively. Significant predictors for HCC identified using a multiple Cox regression analysis were age ≥50 years (hazard ratio (HR): 2.34) and α-fetoprotein (AFP) ≥8 ng/mL (HR: 2.05). The incidence rate of HCC was 8.67-fold higher in patients with age ≥50 years and AFP ≥8 ng/mL (3.14 per 100 person-years) than those with age <50 years and AFP <8 ng/mL (0.36 per 100 person-years). Conclusions: Cirrhotic CHB patients with age <50 years and AFP <8 ng/mL had the lowest annual incidence of HCC. However, those with age ≥50 years or/and AFP ≥8 ng/mL had a significantly higher risk for HCC development and warrant a careful surveillance schedule.https://www.mdpi.com/2075-4418/12/9/2085chronic hepatitis Bcirrhosiscumulative incidenceincidence rateriskhepatocellular carcinoma |
| spellingShingle | Yuh-Ying Liu Chih-Lang Lin Cheng-Hao Weng Pei-Hung Chang Cheng-Hung Chien Kuang-Chen Huang Man-Chin Hua Ching-Chih Hu Older Age and High α-Fetoprotein Predict Higher Risk of Hepatocellular Carcinoma in Chronic Hepatitis-B-Related Cirrhotic Patients Receiving Long-Term Nucleos(t)ide Analogue Therapy Diagnostics chronic hepatitis B cirrhosis cumulative incidence incidence rate risk hepatocellular carcinoma |
| title | Older Age and High α-Fetoprotein Predict Higher Risk of Hepatocellular Carcinoma in Chronic Hepatitis-B-Related Cirrhotic Patients Receiving Long-Term Nucleos(t)ide Analogue Therapy |
| title_full | Older Age and High α-Fetoprotein Predict Higher Risk of Hepatocellular Carcinoma in Chronic Hepatitis-B-Related Cirrhotic Patients Receiving Long-Term Nucleos(t)ide Analogue Therapy |
| title_fullStr | Older Age and High α-Fetoprotein Predict Higher Risk of Hepatocellular Carcinoma in Chronic Hepatitis-B-Related Cirrhotic Patients Receiving Long-Term Nucleos(t)ide Analogue Therapy |
| title_full_unstemmed | Older Age and High α-Fetoprotein Predict Higher Risk of Hepatocellular Carcinoma in Chronic Hepatitis-B-Related Cirrhotic Patients Receiving Long-Term Nucleos(t)ide Analogue Therapy |
| title_short | Older Age and High α-Fetoprotein Predict Higher Risk of Hepatocellular Carcinoma in Chronic Hepatitis-B-Related Cirrhotic Patients Receiving Long-Term Nucleos(t)ide Analogue Therapy |
| title_sort | older age and high α fetoprotein predict higher risk of hepatocellular carcinoma in chronic hepatitis b related cirrhotic patients receiving long term nucleos t ide analogue therapy |
| topic | chronic hepatitis B cirrhosis cumulative incidence incidence rate risk hepatocellular carcinoma |
| url | https://www.mdpi.com/2075-4418/12/9/2085 |
| work_keys_str_mv | AT yuhyingliu olderageandhighafetoproteinpredicthigherriskofhepatocellularcarcinomainchronichepatitisbrelatedcirrhoticpatientsreceivinglongtermnucleostideanaloguetherapy AT chihlanglin olderageandhighafetoproteinpredicthigherriskofhepatocellularcarcinomainchronichepatitisbrelatedcirrhoticpatientsreceivinglongtermnucleostideanaloguetherapy AT chenghaoweng olderageandhighafetoproteinpredicthigherriskofhepatocellularcarcinomainchronichepatitisbrelatedcirrhoticpatientsreceivinglongtermnucleostideanaloguetherapy AT peihungchang olderageandhighafetoproteinpredicthigherriskofhepatocellularcarcinomainchronichepatitisbrelatedcirrhoticpatientsreceivinglongtermnucleostideanaloguetherapy AT chenghungchien olderageandhighafetoproteinpredicthigherriskofhepatocellularcarcinomainchronichepatitisbrelatedcirrhoticpatientsreceivinglongtermnucleostideanaloguetherapy AT kuangchenhuang olderageandhighafetoproteinpredicthigherriskofhepatocellularcarcinomainchronichepatitisbrelatedcirrhoticpatientsreceivinglongtermnucleostideanaloguetherapy AT manchinhua olderageandhighafetoproteinpredicthigherriskofhepatocellularcarcinomainchronichepatitisbrelatedcirrhoticpatientsreceivinglongtermnucleostideanaloguetherapy AT chingchihhu olderageandhighafetoproteinpredicthigherriskofhepatocellularcarcinomainchronichepatitisbrelatedcirrhoticpatientsreceivinglongtermnucleostideanaloguetherapy |